Natera
Cell-free DNA testing company building molecular diagnostics across oncology, women's health, and organ health, including Signatera, Panorama, and Prospera.
About
Natera describes itself as a global leader in cell free DNA testing, developing molecular diagnostic tests that help inform more personalized health care decisions. The work spans three areas: oncology, women's health, and organ health.
In oncology the portfolio includes Signatera for molecular residual disease testing, Altera for tumor genomic profiling, and Empower for hereditary cancer screening. Women's health covers Panorama for noninvasive prenatal testing, Horizon for carrier screening, Vistara for single gene NIPT, and Anora for miscarriage testing. Organ health covers the Prospera portfolio for kidney, heart, lung, and liver transplant assessment, alongside Renasight, a kidney gene panel.
Testing runs in CAP and CLIA certified laboratories, and the company says its tests have been validated across more than 400 peer reviewed publications. Hiring spans laboratory, clinical, and commercial roles alongside software engineering.
